ESTRO 2025 - Abstract Book

S1542

Clinical – Mixed sites & palliation

ESTRO 2025

• Patient satisfaction : Median score of 7 out of 10 (range: 0 – 10, mean: 7.1). Notably, three patients reported maximum satisfaction with a score of 10. • Clinical improvements : Four patients achieved significant pain relief, with VAS ≤ 2 in treated areas. Toxicity : No adverse effects related to Magnetolith® were reported. Specific cases : One patient with sacral insufficiency fractures reduced VAS from 8 to 0. Another patient showed significant improvement in neuropathic thigh pain (VAS 10 to 5) and spinal pain, enabling a reduction in morphine use. However, two patients experienced limited or no benefit.

Conclusion: These preliminary results suggest that Magnetolith® is a safe and well-tolerated option for gynecological cancer patients with chronic pain post-radiotherapy. Significant pain relief was observed in cases of insufficiency fractures and refractory neuropathic pain, supporting its potential role as an adjuvant therapy. The high satisfaction rates, including three patients reporting maximum satisfaction, highlight the potential impact on quality of life. Further studies are warranted to validate these findings.

Keywords: Magnetolith®, cervical cancer, radiotherapy pain

3048

Digital Poster Effectiveness and Safety of Stereotactic Body Radiotherapy for Bone Metastases: Monocentric Clinical Cohort from Czech Republic Marek Slavik 1,2 , Petr Burkon 1,2 , Iveta Selingerova 3 , Tomas Prochazka 1,2 , Miroslav Vrzal 1 , Jaroslava Stankova 1 , Petr Dvoracek 1 , Ludmila Hynkova 1,2 , Miroslava Slavikova 1 , Pavel Slampa 1,2 , Dukagjin M. Blakaj 4 1 Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic. 2 Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. 3 Department of Clinical Trials, Masaryk Memorial Cancer Institute, Brno, Czech Republic. 4 Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, USA Purpose/Objective: The objective of this study is to evaluate the clinical outcomes and treatment safety of stereotactic body radiotherapy (SBRT) with a simultaneous integrated boost (SIB) for bone metastases. Material/Methods: This retrospective analysis included 89 patients treated at Masaryk Memorial Cancer Institute between 2018 and mid-2022. SBRT was delivered to patients with spinal or non-spinal bone metastases, with treatment decisions